NDA 210730 · Trevena
Olinvyk
Oliceridine · Intravenous
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Aug 7, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
38
3 Phase 3, 8 recruiting
FAERS reports
4
4 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OLINVYK Addiction, Abuse, and Misuse Because the use of OLINVYK exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of OLINVYK, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of OLINVYK are essential [see Warnings and Precautions ( 5.2 )]. Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous...
What it is approved for
From the label in effect Dec 31, 2025.
OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration [see Warnings and Precautions ( 5.1 )] , and persist over the course of therapy, reserve opioid analgesics, including OLINVYK, for use in patients for whom alternative treatment options are ineffective, not management of pain. The cumulative total daily dose should not exceed 27 mg, as total daily doses greater than 27 mg may increase the risk for QTc interval prolongation [see Warnings and Precautions ( 5.5 ] . OLINVYK is an opioid agonist indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. ( 1 ) Limitations of Use ( 1 ) Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including OLINVYK, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.( 1 , 5.1 ) The cumulative total daily dose should not exceed 27 mg. ( 2.1 , 2.2 , 5.5 ).
Mechanism: Oliceridine is a full opioid agonist and is relatively selective for the mu-opioid receptor. The principal therapeutic action of oliceridine is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oliceridine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory, and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- OLINVYK · OLICERIDINE 30MG/30ML (1MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- OLINVYK · OLICERIDINE 1MG/ML (1MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- OLINVYK · OLICERIDINE 2MG/2ML (1MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Oliceridine" as an intervention, any sponsor and status, largest first.
- A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute PainPivotal-lookingCompleted
Trevena Inc.Industry
NCT02656875 · 768 participants · Start Dec 2015 · Primary completion May 2017
Drug: TRV130 · For: Acute Pain
Sites: Mobile, Alabama; Pasadena, California; Miami, Florida · 10 sites in all
- the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal SurgeryPivotal-lookingNot yet recruiting
Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT06530563 · 606 participants (planned) · Start Aug 2025 · Primary completion Apr 2026
Drug: Oliceridine Injection [Olinvyk]; Sufentanil Citrate · For: Acute Pain; Opioid Analgesic Adverse Reaction
Sites: Changsha, China
- Respiratory Safety of Oliceridine During Sedated Gastrointestinal EndoscopyPivotal-lookingCompleted
Shiyou WeiAcademic, hospital or other
NCT07187765 · 508 participants · Start Sep 22, 2025 · Primary completion Nov 30, 2025
Drug: Oliceridine; Sufentanil · For: Hypoxemia During Surgery; Gastrointestinal Endoscopy
Sites: Tianmen, China
- Effect of Postoperative Analgesia of Oliceridine Fumarate for Gastrointestinal Function Recovery in Patients Undergoing Lumbar Spine SurgeryPivotal-lookingRecruiting
Xijing HospitalAcademic, hospital or other
NCT07307495 · 428 participants (planned) · Start Mar 30, 2026 · Primary completion Jul 1, 2027
Drug: Sufentanil; Oiceridine · For: Oliceridine Fumarate
Sites: Xi'an, China
- Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After BunionectomyPivotal-lookingCompleted
Trevena Inc.Industry
NCT02815709 · 418 participants · Start May 2016 · Primary completion Dec 2016
Drug: Oliceridine; Placebo and 1 more · For: Acute Pain
Sites: Phoenix, Arizona; Anaheim, California; Pasadena, California · 7 sites in all
- Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After AbdominoplastyPivotal-lookingCompleted
Trevena Inc.Industry
NCT02820324 · 407 participants · Start May 2016 · Primary completion Dec 2016
Drug: Oliceridine; Placebo and 1 more · For: Acute Pain
Sites: Phoenix, Arizona; Pasadena, California; Pasadena, Maryland · 5 sites in all
- A Study of TRV130 for the Treatment of Pain After BunionectomyPivotal-lookingCompleted
Trevena Inc.Industry
NCT02100748 · 333 participants · Start Apr 2014 · Primary completion Oct 2014
Drug: TRV130; Morphine and 1 more · For: Acute Pain
Sites: Phoenix, Arizona; Pasadena, Maryland; Austin, Texas · 4 sites in all
- Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lung ResectionPivotal-lookingRecruiting
Tianjin Medical University General HospitalAcademic, hospital or other
NCT07018375 · 320 participants (planned) · Start Jan 6, 2026 · Primary completion Mar 31, 2027
Drug: Oliceridine; Sufentanil · For: Chronic Postsurgical Pain
Sites: Baoding, China; Tangshan, China; Tianjin, China · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaphylactic shock2
- epilepsy1
- respiratory depression1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review.
Daksla N, Wang A, Jin Z, et al. · Drug Des Devel Ther 2023 · Systematic Review
- APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.
Singla NK, Skobieranda F, Soergel DG, et al. · Pain Pract 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Tegileridine versus Oliceridine for Acute Postoperative Pain Management in Patients After Minimally Invasive Esophagectomy: A Preliminary Randomized Controlled Trial.
Qiu Y, Zhang Y, Huang C, et al. · Drug Des Devel Ther 2025 · Comparative Study, Randomized Controlled Trial
- Effect of Oliceridine Combined with Sufentanil on Patient-Controlled Intravenous Analgesia in Elderly Patients After Laparoscopic Radical Resection of Rectal Cancer: A Prospective Randomized Controlled Study.
Tian Y, Hu J, Pan H, et al. · Drug Des Devel Ther 2025 · Randomized Controlled Trial
- A Comparative Evaluation of the Safety and Efficacy of Oliceridine and Sufentanil in Gastrointestinal Endoscopy: A Single-Center, Randomized Controlled Trial.
Ma B, Li Y, Leng C, et al. · Drug Des Devel Ther 2025 · Comparative Study, Randomized Controlled Trial
- Comparison of Oliceridine and Morphine in Postoperative Analgesia in Laparoscopic Total Hysterectomy, a Randomized Double-Blind Controlled Trial.
Duan J, Wang X, Hou C, et al. · Drug Des Devel Ther 2025 · Comparative Study, Randomized Controlled Trial
Sponsor: Trevena
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.